TABLE 1.

Summary of the Cohorts Used for Analysis of Malignancies

Cohort		Description
Induction	Patients	Patients who received either placebo or tofacitinib 10 mg twice daily in OCTAVE Induction 1 or 2 for 8 weeks
	Treatment groups	Placebo, tofacitinib 10 mg twice daily
	Exposure time	0–9 weeks
Maintenance	Patients	Patients who completed induction treatment with either placebo or tofacitinib 10 mg twice daily demonstrated a clinical response and entered the phase 3 maintenance study
	Treatment groups	Placebo, tofacitinib 5 mg twice daily, tofacitinib 10 mg twice daily
	Exposure time	0–53 weeks
Overall	Patients	All patients who received at least one dose of tofacitinib 5 mg or 10 mg twice daily in induction studies, the maintenance study, and ongoing OLE studies
	Treatment groups	Tofacitinib All, predominant-dose tofacitinib 5 mg twice daily, predominant-dose tofacitinib 10 mg twice daily
	Exposure time	Up to 6.8 years

Abbreviations: OLE, open-label, long-term extension